Effects of Shakubactril valsartan sodium tablets combined with folic acid on blood pressure,sdLDL-C levels,and plasma Hcy in patients with H-type hypertension
Objective To explore the effect of captopril,valsartan and folic acid treatment on blood pressure,SDLDL-C(Small dense low-density lipoprotein cholesterol)levels and plasma Hcy(Plasma homocysteine)in patients with H-type hypertension. Methods A total of 176 patients with H-type hypertension who were treated at the hospital from October 2021 to September 2022 were selected as subjects. They were divided into two groups using a randomized double-blind method. The control group received treatment with savo and valtracortin sodium tablets. While the the research group received treatment with folic acid in addition to the control group. Results The overall clinical efficacy rate of the subjects in the research group was 92.05％,which was significantly higher than that in the control group(x2=3.965,P<0.05). The systolic and diastolic blood pressure of the subjects in the study group were lower than those in the control group after treatment,and the difference was statistically significant(t=6.007,4.186,P<0.05). After treatment,the levels of TC,TG,HDL-C,LDL-C,and sdLDL-C in the study group were lower than those in the control group,and the difference was statistically significant(t=19.705,19.105,13.304,13.466,10.713,P<0.05). After treatment,the serum inflammatory markers IL-6 and TNF-α,as well as both hs-CRP and Hcy were superior to those in the control group,and the difference was statistically significant(t=19.705,19.105,13.304,13.466, 10.713,P<0.05). Conclusion Shakubatroxobin sodium tablets combined with folic acid have shown positive clinical effects in treating H-type hypertension. This treatment effectively reduces blood pressure ,improves the blood lipid levels,and reduces the serum inflammatory markers in patients,due to its high clinical value. It is worth promoting this treatment widely.
万方数据
维普
